Telos Capital Management Inc. Has $8.08 Million Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Telos Capital Management Inc. boosted its position in IQVIA Holdings Inc. (NYSE:IQV) by 0.5% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 38,233 shares of the medical research company’s stock after purchasing an additional 180 shares during the period. Telos Capital Management Inc.’s holdings in IQVIA were worth $8,084,000 as of its most recent filing with the SEC.

Several other hedge funds have also bought and sold shares of IQV. Norges Bank acquired a new stake in IQVIA in the 4th quarter valued at about $383,705,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its holdings in shares of IQVIA by 339.6% during the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 2,067,195 shares of the medical research company’s stock worth $478,308,000 after purchasing an additional 1,597,003 shares during the period. Morningstar Investment Services LLC increased its holdings in shares of IQVIA by 96.9% during the fourth quarter. Morningstar Investment Services LLC now owns 1,231,916 shares of the medical research company’s stock worth $286,704,000 after purchasing an additional 606,333 shares during the period. Capital Research Global Investors increased its holdings in shares of IQVIA by 42.2% during the fourth quarter. Capital Research Global Investors now owns 1,995,269 shares of the medical research company’s stock worth $461,675,000 after purchasing an additional 592,372 shares during the period. Finally, Cadian Capital Management LP bought a new position in shares of IQVIA during the fourth quarter worth approximately $70,108,000. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at IQVIA

In related news, insider Eric Sherbet sold 1,300 shares of the business’s stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total value of $320,229.00. Following the transaction, the insider now owns 19,536 shares in the company, valued at $4,812,302.88. The transaction was disclosed in a document filed with the SEC, which is available through this link. 1.60% of the stock is owned by company insiders.

IQVIA Trading Up 0.3 %

Shares of NYSE:IQV traded up $0.76 during mid-day trading on Friday, reaching $251.55. 1,194,435 shares of the company’s stock were exchanged, compared to its average volume of 799,551. The firm has a market capitalization of $45.86 billion, a price-to-earnings ratio of 34.36, a PEG ratio of 2.37 and a beta of 1.49. The business’s fifty day moving average price is $231.33 and its 200-day moving average price is $234.33. The company has a debt-to-equity ratio of 1.80, a quick ratio of 0.85 and a current ratio of 0.85. IQVIA Holdings Inc. has a twelve month low of $167.42 and a twelve month high of $261.73.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Monday, July 22nd. The medical research company reported $2.64 EPS for the quarter, topping analysts’ consensus estimates of $2.57 by $0.07. The company had revenue of $3.81 billion for the quarter, compared to analyst estimates of $3.79 billion. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. IQVIA’s revenue was up 2.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.22 earnings per share. On average, research analysts predict that IQVIA Holdings Inc. will post 10.24 EPS for the current fiscal year.

Analyst Ratings Changes

IQV has been the topic of several recent research reports. Barclays raised their target price on shares of IQVIA from $255.00 to $275.00 and gave the stock an “overweight” rating in a report on Tuesday, July 23rd. Robert W. Baird lifted their price objective on shares of IQVIA from $235.00 to $251.00 and gave the company a “neutral” rating in a research note on Tuesday, July 23rd. Jefferies Financial Group cut shares of IQVIA from a “buy” rating to a “hold” rating and decreased their price objective for the company from $266.00 to $242.00 in a research note on Wednesday, July 24th. The Goldman Sachs Group assumed coverage on shares of IQVIA in a research note on Thursday, June 6th. They issued a “buy” rating and a $270.00 price objective on the stock. Finally, Evercore ISI lifted their price objective on shares of IQVIA from $230.00 to $270.00 and gave the company an “outperform” rating in a research note on Tuesday, July 23rd. Five equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, IQVIA presently has an average rating of “Moderate Buy” and a consensus price target of $265.67.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.